Discontinuations and Withdrawal [Design Issues]

posted by kvgreddy06 – India, 2013-10-09 15:09 (4642 d 02:36 ago) – Posting: # 11631
Views: 4,711

Hello All

If a drug contain combination of two formulations [IR+ CR] for that drug how can justify the Discontinuation and Withdrawal criteria in case of emesis?

Generally as per guidelines

For IR fomulations we go through as subject experiences emesis within twice the median tmax of X drug after administration of IP.

For CR formulations: subject experiences emesis any time within the labelled dosing interval of the IP


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
163 visitors (0 registered, 163 guests [including 17 identified bots]).
Forum time: 17:46 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5